研究单位：[1]Shanghai Miracogen Inc.[2]Fifth Medical Center of PLA General Hospital Beijing, Beijing, China, 100071[3]Peking Union Medical College Hospital Beijing, Beijing, China, 100730[4]Chongqing Cancer Hospital Chongqing, Chongqing, China, 400030[5]Guangdong Provincial People's Hospital Guangzhou, Guangdong, China, 510080[6]The Fourth hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050035河北医科大学第四医院[7]Henan Cancer Hospital Zhengzhou, Henan, China, 450008[8]The First Affiliated Hosipital of Zhengzhou University Zhengzhou, Henan, China, 450052[9]Hunan Cancer Hospital Changsha, Hunan, China, 410013[10]Jiangsu Province Hospital Nanjing, Jiangsu, China, 210029[11]Xuzhou Central Hospital Xuzhou, Jiangsu, China, 221009[12]Jilin Cancer Hospital Changchun, Jilin, China, 130012[13]Liaoning Cancer Hospital & Institute Shengyang, Liaoning, China, 110801[14]Jinan Central Hospital Affiliated to Shandong University Jinan, Shandong, China, 250013[15]Shanghai East Hospital Shanghai, Shanghai, China, 200120[16]Tianjin Medical University Cancer Institute & Hospital Tianjing, Tianjing, China, 300060[17]Zhejiang Cancer Hospital Hangzhou, Zhejiang, China, 310005[18]The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou, Zhejiang, China, 310009[19]Sir Run Run Shaw Hospital Hangzhou, Zhejiang, China, 310020[20]Anhui Provincial Hospital Hefei, Anhui, China, 230001
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-positive unresectable locally advanced or metastatic breast cancer.
